Biotech firms can have trouble maintaining reliable access to capital throughout the long, unpredictable development, testing, and approval process. J.W. Verret, GMU law school professor and member of the SEC’s investor advisory committee, has ideas about how to help biotech and other small-cap companies access the public and exempt markets more efficiently.
Verret talks about why current securities regulations, like Reg A and Reg FD, hamper small-cap companies and hobble their search for liquidity. He discusses small changes, and better outreach from the SEC to small-cap firms, that could tip the scales and help match money with innovations that could improve lives—a high-risk, potentially high-reward industry, biotech can provide life-saving innovations when success finally materializes.
Law X.0 is a podcast focused on the leading edge of law and the legal industry. Stay tuned for more emerging legal topics.
Hosts: Dori Goldstein and Eleanor Tyler
Guest: J.W. Verret, associate professor of law, Antonin Scalia Law School, George Mason University
Producer: RJ Jewell